FDA approves AZ's Farxiga in new heart failure prevention us...

The FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in adults with type 2 diabetes and other cardiovascular risks.<

Artificial pancreas outperforms current tech in type 1 diabe...

An “artificial pancreas” has proved to be more effective at controlling blood sugar than injections with insulin by patients or with a pump, in an international trial mainly funded by the U

Pfizer inks deal with Ionis and Akcea for potential blockbus...

Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to treat patients with certain cardiovascular and metabolic diseases

Novo’s new oral GLP-1 Rybelsus still has obstacles to overco...

Novo and Sanofi make case for hypo-reducing insulins at EASD

Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability t

Giving patients a sense of belonging

Clinical research professional and patient advocate Kristina Wolfe tells us how pharma can collaborate better with patients and give them a place in the healthcare conversation.